ARCHIVES

ASCO’s Lichter Says. Dingell, Stupak Urge FDA To “Act With Due Haste To Avoid Endangering Patients” Steered To ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 09 | March 7, 2008

Download PDF Visit The Full Archive

Related Articles

Report on Carcinogens: Advisors Recommend Tobacco, UV Light, Tamoxifen, For Report

November 7, 1997

Amgen Pays $24.9 Million To Settle Kickback Charges

April 19, 2013

DCCP Board Gives Concept Approval To RFA For Biochemical Epidemiolgy, New And Recompeting Contract Program

September 23, 1983

A Year at NCI: Harold Varmus Reflects On Provocative Questions, The Duke Scandal, Financial Disaster And Grant Review

July 22, 2011

Spending Measures Include Provisions On Ethics For NIH Extramural Scientists.

July 11, 2008

Campath Improves PFS In B-Cell CLL In Phase III Trial

January 26, 2007